Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aktiferrin F is an oral combination drug designed to treat iron deficiency anemia and latent deficiencies of iron and folic acid, particularly relevant during pregnancy and lactation. Its active components include ferrous sulfate, DL-serine, folic acid, and vitamin B12. Ferrous sulfate provides elemental iron, a vital mineral for the synthesis of hemoglobin, which is essential for oxygen transport in red blood cells. DL-serine acts synergistically to enhance the absorption of iron from the gastrointestinal tract into the bloodstream. Folic acid and vitamin B12 are crucial for the formation of new cell nuclei and the synthesis of nucleic acids, thereby supporting erythropoiesis (red blood cell production) and complementing the iron's action. The drug is administered orally, typically in capsule form.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Aktiferrin F.